(VIANEWS) – Recently, Cronos Group (NASDAQ: CRON) experienced an unexpected rise in stock price over 10 sessions. On August 24 it traded at EUR1.7, but rose 24.12% by 11:20 EST Friday morning to reach EUR2.11. This upward trend comes after four consecutive sessions of losses on NASDAQ, where it currently sits down by 0.53% to EUR13,822.21.
Cronos Group stock has seen a recent upswing, yet is still 42.48% below its 52-week high of EUR3.62. While this indicates some positive change, more needs to be done before reaching previous highs.
Cronos Group’s performance will likely be closely scrutinized by investors due to its involvement in the rapidly expanding cannabis industry. With legalization taking effect around the globe and demand increasing for cannabis-related products worldwide, investors could see strong future growth for Cronos Group. But before making any decisions they should carefully assess their own risk tolerance and financial goals before taking any actions.
About Cronos Group
Cronos Group Inc. is a cannabinoid company founded in 2012 in Toronto, Canada that manufactures, distributes, and markets hemp-derived nutritional supplements and cosmetic products through the Lord Jones brand in the US market. Additionally, they cultivate, manufacture, and market cannabis-related products for medical and adult-use markets under PEACE NATURALS wellness platform and Spinach brand respectively. The business was started up and has operations worldwide.
Yearly Analysis
Cronos Group stock has fallen significantly since reaching a 52-week high of EUR3.62, but is higher than its 52-week low of EUR1.64. This indicates a period of increased volatility within the past year.
Cronos Group’s sales growth projections predict negative growth of 12.5% this year and an uptick in 23.1% over the coming year, which may signal that they may be facing challenges near term but have the ability to make significant strides forward over time.
Cronos Group currently stands with an EBITDA of -2.27, which indicates it is currently unprofitable for investors to consider as they assess Cronos Group for investment purposes. Investors may take notice, yet keep in mind that many cannabis businesses are still in their early stages and may not yet be profitable.
Cronos Group stock may be considered high-risk due to its current negative EBITDA and historical volatility; however, sales growth forecasted for next year suggests potential positivity for its future prospects.
Technical Analysis
Cronos Group’s stock has experienced a steep price decrease, falling below both its 50-day and 200-day moving averages, which indicates it may be in an ongoing downtrend and continue to lose value. Furthermore, volume trading activity was much lower than normal; suggesting less interest and trading activity from shareholders in Cronos’ shares.
This stock’s volatility has been relatively low, with an intraday variation average of just 0.79% in the past week and 0.75 in terms of months gone by; however, its highest amplitude of average volatility measured 3.79% last week; which could signal an uptick in volatility over time.
Cronos Group stock is currently considered overbought according to the stochastic oscillator, signalling potential signs that it could soon experience a correction or reverse trend. Investors should exercise caution and monitor closely prior to making any investment decisions about this stock.
Quarter Analysis
Cronos Group has experienced a decline in sales growth for both the current quarter and subsequent ones, which may cause concern among investors, suggesting that revenues may not be growing at an acceptable pace.
However, growth estimates for both this quarter and next quarter are rather impressive: 80% and 95.2%, respectively. This could signal an opportunity for the company and lead to increased revenues over time.
Importantly, Cronos Group’s year-on-year quarterly revenue growth has also decreased by 11.9% year-on-year – perhaps this indicates increased competition in their industry or their products are no longer reaching consumers as effectively.
Overall, investors should take caution before investing in Cronos Group. Although their growth estimates suggest potential for future revenue increases, their negative sales growth in current and upcoming quarters warrants further investigation to identify any possible catalysts of growth within their competitive landscape or product offering that might support greater returns for growth.
Equity Analysis
Cronos Group currently boasts an EPS of EUR-0.39 for its trailing twelve months earnings per share (EPS), suggesting it may not be producing sufficient profits to sustain operations and offer returns to shareholders.
As previously discussed, the company’s return on equity (ROE) for the twelve trailing months stands at an unfavorable negative -12.1%. A negative ROE indicates that its profitability is not being maximized efficiently or effectively and shareholder money is not being utilized efficiently to create returns for shareholders.
These metrics suggest that Cronos Group may be facing financial difficulties and is unlikely to provide returns for investors looking for returns from their investment. Before making any definitive investment decisions, investors should conduct further research and analysis in order to identify any positive factors which might help offset negative indicators such as those described above.
More news about Cronos Group (CRON).
